Q3 2025 Biofrontera Inc Earnings Call Transcript

Nov 13, 2025 / 03:00 PM GMT

Transcript 8-K10-Q

Key Points

Positve

Biofrontera Inc (BFRI) anticipates strong revenue growth in the fourth quarter of 2025, following a transient revenue dip.
The company has made significant progress in advancing its position as a premier dermatology company with a revamped sales approach.
Biofrontera Inc (BFRI) has expanded its installed base of Rotolet lamps, supporting recurring high-margin sales of Ameluz gel.
The company has completed patient enrollment in key clinical trials, including a Phase 3 trial for actinic keratosis and a Phase 2B trial for acne vulgaris.
Biofrontera Inc (BFRI) secured an $11 million investment from healthcare-focused institutional investors, enhancing its financial position.

Negative

Year-to-date revenues were approximately flat compared to the same period in 2024, indicating a lack of growth.
The third quarter of 2025 saw a 22% decline in revenues compared to the same quarter in 2024 due to a lack of price increase opportunities.
Total operating expenses increased, driven by higher legal costs related to patent claims.
The company reported a net loss of $6.6 million for the third quarter of 2025, an increase from the previous year's loss.
Selling, general, and administrative expenses rose to $10.4 million in Q3 2025, up from $8.4 million in Q3 2024, primarily due to increased legal expenses.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BFRI.OQ - Biofrontera Inc
Q3 2025 Biofrontera Inc Earnings Call
Nov 13, 2025 / 03:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the BioFrontera Inc. 3rd quarter 2025 financial results in business update conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the key, followed by zero.

After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded.

I would now like to turn the conference over to Ben Shamsian with Lithlam Partners Investor Relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good morning and welcome

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.